How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
A small number of patients using infliximab (Remicade) have had very severe hepatic reactions, according to a revision of the package prescribing information.
In announcing the new safety information, the Food and Drug Administration and Centocor Inc. said there have been 35 cases of severe hepatic reactions in patients...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
